The relative role of peripheral blood and bone marrow for monitoring molecular evidence of disease in follicular lymphoma by quantitative real-time polymerase chain reaction.
Peripheral blood (PB) and bone marrow (BM) are used interchangeably for t(14;18) (IgH/BCL-2) molecular monitoring in follicular lymphoma (FL) and detection of rearrangement after treatment has been correlated to increased risk of relapse. To determine the relative value of each tissue, MBR t(14;18) was quantified by real-time polymerase chain reaction in 52 simultaneous paired PB and BM samples from 38 FL patients. In total, 79% of sample pairs taken in remission (n = 19) or when no morphological disease was evident in the BM (n = 29) had t(14;18) copy number within one log difference and the median difference was small. These findings suggest that, in remission, PB may be adequately monitored. In general, however, higher copy number was detected in BM than in the corresponding PB sample.
Cancer Research UK--Medical Oncology Unit, Department of Medical Oncology, Charterhouse Square, London EC1M 6BQ, UK.
Karin E
KE
Summers
Andrew J
AJ
Davies
Janet
J
Matthews
Michael J
MJ
Jenner
Victoria
V
Cornelius
John A
JA
Amess
Andrew J
AJ
Norton
Ama Z S
AZ
Rohatiner
Jude
J
Fitzgibbon
T Andrew
TA
Lister
Lindsey K
LK
Goff
D001769:Blood; D001853:Bone Marrow / Q000473:pathology*; D019457:Chromosome Breakage; D002883:Chromosomes, Human, Pair 14 / Q000235:genetics*; D002887:Chromosomes, Human, Pair 18 / Q000235:genetics*; D015321:Gene Rearrangement; D006801:Humans; D008224:Lymphoma, Follicular / Q000235:genetics* / Q000473:pathology; D018365:Neoplasm, Residual; D016133:Polymerase Chain Reaction / Q000379:methods*